Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 4/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979011 | 0.84 | PDGFRB (0.39) | PDE10AEGFRMAP4K4KMT2APDGFRB | |
| SCHEMBL14372220 | 0.83 | PDE10A (0.36) | PDE10AEGFRMAP4K4PDE2APDE7A | |
| SCHEMBL15979009 | 0.83 | KCNH2 (0.39) | EGFRMAP4K4 | |
| SCHEMBL13865284 | 0.80 | PDE10A (0.39) | PDE10AEGFRMAP4K4CYP1A2KMT2A | |
| SCHEMBL15979006 | 0.80 | EGFR (0.33) | PDE10AEGFRMAP4K4PDGFRBPDGFRA | |
| SCHEMBL15979008 | 0.78 | KDM4E (0.31) | — | |
| SCHEMBL20687532 | 0.77 | PDGFRB (0.34) | MAP4K4PDGFRBPDGFRA | |
| SCHEMBL14372223 | 0.77 | CSF1R (0.34) | PDE10AMAP4K4PDGFRBPDGFRAPDE2A | |
| SCHEMBL15979010 | 0.75 | PDE10A (0.36) | PDE10AEGFRMAP4K4CYP1A2KMT2A | |
| SCHEMBL4298144 | 0.75 | KCNH2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | PDE10A 1995/4885EGFR 3139/4885MAP4K4 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.